CAMBRIDGE, Mass. - Moderna’s COVID-19 vaccine remained 93% effective against symptomatic illness six months after the second dose, but amid the ongoing spread of the highly contagious delta variant, ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...
Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback